Five Years of Cancer Drug Approvals
Sham Mailankody(Memorial Sloan Kettering Cancer Center), Vinay Prasad(University of California, San Francisco)
Cited by 287
Related Papers
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
|JAMA Internal Medicine|2017|497
The high price of anticancer drugs: origins, implications, barriers, solutions
|Nature Reviews Clinical Oncology|2017|430
GPRC5D-Targeted CAR T Cells for Myeloma
|New England Journal of Medicine|2022|383
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
|JAMA Oncology|2015|309
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
|JAMA Otolaryngology–Head & Neck Surgery|2014|301